Atypical mycobacterial and fungal infections in cystic fibrosis

Seminars in Respiratory and Critical Care Medicine

Volumn 30, Issue 5, 2009, Pages 539-546

  Whittaker, Laurie A ^a   Teneback, Charlotte ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Cystic fibrosis; Fungi; Lung disease; Nontuberculous mycobacteria

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANTIBIOTIC AGENT; AZITHROMYCIN; CASPOFUNGIN; CEFOXITIN; CLARITHROMYCIN; ETHAMBUTOL; FLUCONAZOLE; GAMMA INTERFERON; ITRACONAZOLE; POSACONAZOLE; RIFAMPICIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; BACTERIAL INFECTION; BACTERIUM CULTURE; CANDIDIASIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DETERIORATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HOSPITALIZATION; HUMAN; LUNG INFECTION; MYCOBACTERIUM; MYCOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPUTUM;

CYSTIC FIBROSIS; HUMANS; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOSES; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; SPUTUM;

EID: 70350456264     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0029-1238912     Document Type: Review

References (64)

1. Rowe S M., Miller S, Sorscher E J. Cystic fibrosis. N Engl J Med 2005 352 1992-2001 (Pubitemid 40638370)
2. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979 119 107-159
3. Guay D R. Nontuberculous mycobacterial infections. Ann Pharmacother 1996 30 819-830
4. Olivier K N., Weber D J., Wallace R J. Jr et al, Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria, I: Multicenter prevalence study in cystic fibrosis. [see comment]. Am J Respir Crit Care Med 2003 167 828-834
5. Olivier K N., Yankaskas J R., Knowles M R. Nontuberculous mycobacterial pulmonary disease in cystic fibrosis. Semin Respir Infect 1996 11 272-284
6. Sexton P, Harrison A C. Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J 2008 31 1322-1333
7. Fowler S J., French J, Screaton N J. et al. Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics. Eur Respir J 2006 28 1204-1210
8. Torrens J K., Dawkins P, Conway S P., Moya E. Non-tuberculous mycobacteria in cystic fibrosis. Thorax 1998 53 182-185
9. Chalermskulrat W, Sood N, Neuringer I P. et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006 61 507-513
10. Griffith D E., Aksamit T, Brown-Elliott B A. et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007 175 367-416
11. Kent P, Kubica G. Public health mycobacteriology: a guide for the level III laboratory. In: Services UDoHaH, ed. Centers for Disease Control and Prevention. 1985
12. Whittier S, Hopfer R L., Knowles M R., Gilligan P H. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 1993 31 861-864
13. Whittier S, Olivier K, Gilligan P, Knowles M, Della-Latta P, The Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Proficiency testing of clinical microbiology laboratories using modified decontamination procedures for detection of nontuberculous mycobacteria in sputum samples from cystic fibrosis patients. J Clin Microbiol 1997 35 2706-2708
14. Bange F C., Kirschner P, Böttger E C. Recovery of mycobacteria from patients with cystic fibrosis. J Clin Microbiol 1999 37 3761-3763
15. Coelho A G., Zamarioli L A., Reis C M., Nascimento A C., Rodrigues J dosS. Gene probes versus classical methods in the identification of mycobacteria. J Bras Pneumol 2008 34 922-926
16. Peter-Getzlaff S, Lüthy J, Böddinghaus B, Böttger E C., Springer B. Development and evaluation of a molecular assay for detection of nontuberculous mycobacteria by use of the cobas amplicor platform. J Clin Microbiol 2008 46 4023-4028
17. Gilljam M, Berning S E., Peloquin C A., Strandvik B, Larsson L O. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J 1999 14 347-351
18. Chatte G, Panteix G, Perrin-Fayolle M, Pacheco Y. Aerosolized interferon gamma for Mycobacterium avium -complex lung disease. Am J Respir Crit Care Med 1995 152 1094-1096
19. Colsky A S., Hanly A, Elgart G, Kerdel F A. Treatment of refractory disseminated Mycobacterium abscessus infection with interferon gamma therapy. Arch Dermatol 1999 135 125-127
20. Condos R, Rom W N., Schluger N W. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997 349 1513-1515
21. Moss R B., Mayer-Hamblett N, Wagener J et al. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 2005 39 209-218
22. Camargos P, Le Bourgeois M, Revillon Y et al. Lung resection in cystic fibrosis: a survival analysis. Pediatr Pulmonol 2008 43 72-76
23. Häusler M, Franke E, Wendt G, Kentrup H, Döhmen H, Kusenbach G. Pneumonectomy in cystic fibrosis. Pediatr Pulmonol 1999 28 376-379
24. Smith M B., Hardin W D. Jr, Dressel D A., Beckerman R C., Moynihan P C. Predicting outcome following pulmonary resection in cystic fibrosis patients. J Pediatr Surg 1991 26 655-659
25. Forslöw U, Geborek A, Hjelte L, Petrini B, Heurlin N. Early chemotherapy for non-tuberculous mycobacterial infections in patients with cystic fibrosis. Acta Paediatr 2003 92 910-915
26. Olivier K N., Weber D J., Lee J H. et al, Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria, II: Nested-cohort study of impact on cystic fibrosis lung disease. [see comment]. Am J Respir Crit Care Med 2003 167 835-840
27. Bartz R R., Love R B., Leverson G E., Will L R., Welter D L., Meyer K C. Pre-transplant mechanical ventilation and outcome in patients with cystic fibrosis. J Heart Lung Transplant 2003 22 433-438
28. Sanguinetti M, Ardito F, Fiscarelli E et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001 39 816-819
29. Taylor J L., Palmer S M. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant 2006 25 985-988
30. Flume P A., Egan T M., Paradowski L J., Detterbeck F C., Thompson J T., Yankaskas J R. Infectious complications of lung transplantation: impact of cystic fibrosis. Am J Respir Crit Care Med 1994 149 1601-1607
31. Navarro J, Rainisio M, Harms H K. et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2001 18 298-305
32. Foweraker J. Recent advances in the microbiology of respiratory tract infection in cystic fibrosis. Br Med Bull 2009 89 93-110
33. Bakare N, Rickerts V, Bargon J, Just-Nübling G. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 2003 46 19-23
34. Stevens D A., Moss R B., Kurup V P. et al, Participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosisstate of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003 37 (Suppl 3) S225-S264
35. Nelson L A., Callerame M L., Schwartz R H. Aspergillosis and atopy in cystic fibrosis. Am Rev Respir Dis 1979 120 863-873
36. Cimon B, Carrère J, Vinatier J F., Chazalette J P., Chabasse D, Bouchara J P. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000 19 53-56
37. Vázquez-Tsuji O, Campos Rivera T, Rondán Zárate A, Mirabal García M. Endobronchitis by Scedosporium apiospermum in a child with cystic fibrosis. Rev Iberoam Micol 2006 23 245-248
38. Horre R, Schaal K P., Siekmeier R, Sterzik B, de Hoog G S., Schnitzler N. Isolation of fungi, especially Exophiala dermatitidis, in patients suffering from cystic fibrosis. A prospective study. Respiration 2004 71 360-366
39. Kusenbach G, Skopnik H, Haase G, Friedrichs F, Döhmen H. Exophiala dermatitidis pneumonia in cystic fibrosis. Eur J Pediatr 1992 151 344-346
40. Diemert D, Kunimoto D, Sand C, Rennie R. Sputum isolation of Wangiella dermatitidis in patients with cystic fibrosis. Scand J Infect Dis 2001 33 777-779
41. Shoseyov D, Brownlee K G., Conway S P., Kerem E. Aspergillus bronchitis in cystic fibrosis. Chest 2006 130 222-226
42. Rüping M J., Vehreschild J J., Cornely O A. Patients at high risk of invasive fungal infections: when and how to treat. Drugs 2008 68 1941-1962
43. Burns J L., Van Dalfsen J M., Shawar R M. et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999 179 1190-1196
44. Hogan D A., Kolter R. PseudomonasCandida interactions: an ecological role for virulence factors. Science 2002 296 2229-2232
45. Agarwal R, Nath A, Aggarwal A N., Gupta D, Chakrabarti A. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with acute severe asthma in a respiratory intensive care unit in North India. Mycoses 2009 Jan 24 [Epub ahead of print]
46. Denning D W., ODriscoll B R., Powell G et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009 179 11-18
47. Máiz L, Cuevas M, Quirce S et al. Serologic IgE immune responses against Aspergillus fumigatus and Candida albicans in patients with cystic fibrosis. Chest 2002 121 782-788
48. Hartl D, Latzin P, Zissel G, Krane M, Krauss-Etschmann S, Griese M. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med 2006 173 1370-1376
49. Travis L B., Roberts G D., Wilson W R. Clinical significance of Pseudallescheria boydii: a review of 10 years experience. Mayo Clin Proc 1985 60 531-537
50. Tadros T S., Workowski K A., Siegel R J., Hunter S, Schwartz D A. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): an emerging mycosis. Hum Pathol 1998 29 1266-1272
51. Guignard S, Hubert D, Dupont B et al. Multifocal Scedosporium apiospermum spondylitis in a cystic fibrosis patient. J Cyst Fibros 2008 7 89-91
52. Symoens F, Knoop C, Schrooyen M et al. Disseminated Scedosporium apiospermum infection in a cystic fibrosis patient after double-lung transplantation. J Heart Lung Transplant 2006 25 603-607
53. Haase G, Skopnik H, Groten T, Kusenbach G, Posselt H G. Long-term fungal cultures from sputum of patients with cystic fibrosis. Mycoses 1991 34 373-376
54. Haase G, Skopnik H, Kusenbach G. Exophiala dermatitidis infection in cystic fibrosis. Lancet 1990 336 188-189
55. Lipp H P. Antifungal agentsclinical pharmacokinetics and drug interactions. Mycoses 2008 51 (Suppl 1) 7-18
56. Herbrecht R, Denning D W., Patterson T F. et al, Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 408-415 (Pubitemid 34851833)
57. Walsh T J., Anaissie E J., Denning D W. et al, Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008 46 327-360
58. Wark P, Wilson A W., Gibson P G. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2001 (4) CD001108 Review. Update in: Cochrane Database Syst Rev 2003;(3):CD001108
59. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007 45 1610-1617
60. Fisher B T., Zaoutis T E. Treatment of invasive candidiasis in immunocompromised pediatric patients. Paediatr Drugs 2008 10 281-298
61. Kauffman C A., Carver P L. Update on echinocandin antifungals. Semin Respir Crit Care Med 2008 29 211-219
62. Marr K A., Boeckh M, Carter R A., Kim H W., Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004 39 797-802
63. Patterson T F., Boucher H W., Herbrecht R et al, European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG) Pfizer Global Aspergillus Study Group. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005 41 1448-1452
64. Lass-Flörl C, Mayr A, Perkhofer S et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2008 52 3637-3641